10x Genomics, Inc. 8-K

What Happened
10x Genomics, Inc. announced its financial results for the quarter ended March 31, 2026 by issuing a press release dated May 7, 2026. The company furnished that press release to the SEC on Form 8-K under Item 2.02 (Results of Operations and Financial Condition); the release is attached as Exhibit 99.1 to the filing.

Key Details

• Press release announcing quarterly results dated May 7, 2026 (filed as Exhibit 99.1).
• Results cover the quarter ended March 31, 2026.
• Filing includes an Inline XBRL cover page (Exhibit 104) for interactive financial data.
• Form 8-K was signed and dated May 7, 2026 by Randy Wu, General Counsel and Secretary.

Why It Matters
This 8-K signals that 10x Genomics has publicly reported its latest quarterly performance—information investors use to assess recent revenue, earnings, cash flow and any management commentary. Retail investors should read the attached press release (Exhibit 99.1) and the Inline XBRL data for detailed figures, then watch for the company’s related quarterly report (Form 10-Q) for full financial statements and disclosures.